All In Biotech

Drug Trial Radar · NCT01666808

FACBC Outcomes for Post Prostatectomy

Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy

Last checked: Nov 20, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Sep 2012

Primary completion

Apr 18, 2022

Study completion Apr 18, 2022

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Aug 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigators will perform a study with 162 patients in whom there is a strong suspicion of prostate cancer that has returned to the body after having a prostatectomy. Half of these patients will have radiotherapy decision-making and delivery per the usual routine, and half of these patients will have the radiotherapy decision and volumes guided by the FACBC test (anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (anti-3- \[18F\]FACBC). The major goal of the investigation is to see whether the FACBC improves the selection and the cancer control rates of post-surgery patients with a rising PSA who undergo radiotherapy.

Conditions

  • Prostate Cancer

Interventions

  • FACBCDrug

    FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings

  • Radiation therapyRadiation

    External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Failure-free SurvivalTime frame: 3-Year post-intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.